HRMY

Harmony Biosciences Holdings, Inc. (HRMY) - Q3 2024 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2024. Harmony Biosciences is a commercial-stage pharmaceutical company focused on rare neurological disorders. Its primary commercial product is WAKIX (pitolisant) for narcolepsy. The company recently expanded its pipeline through the acquisition of Zynerba Pharmaceuticals (completed Oct 2023) and Epygenix Therapeutics (completed April 2024), adding assets for Fragile X Syndrome (ZYN002) and epilepsy (EPX100).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net product revenue increased 16.1% in Q3 and 24.1% in the nine months ended Sept 30, 2024, driven by an 11.2% (Q3) and 19.5% (9M) increase in units shipped and a 7% price increase implemented in January 2024. Growth was partially offset by higher rebates and co-pay assistance.
• Expense Increases:
  • R&D: Increased 45.1% in Q3 and 142.9% in the 9M period. This was primarily due to $43.6M in non-cash In-Process Research and Development (IPR&D) charges related to the Epygenix acquisition and Bioprojet sublicense, plus costs for new assets ZYN002 and EPX100.
  • Sales & Marketing: Increased 17.8% in Q3 due to expanded patient engagement and marketing activities.
  • G&A: Increased 26.8% in Q3, largely driven by a $4.0M increase in legal fees associated with patent litigation.
• Profitability: While Net Income increased in Q3 ($46.1M vs $38.5M), the 9M Net Income decreased slightly ($96.0M vs $102.2M) due to the significant IPR&D charges and higher effective tax rate (29.2% vs 23.5%) driven by non-deductible acquisition costs.
• Debt Refinancing: Interest expense decreased 38.0% in Q3 due to lower rates following the refinancing into the Term Loan A Credit Agreement in 2023.

Guidance, Outlook, and Risks

• Outlook: Management believes existing cash and investments ($504.7M) are sufficient to fund operations for the next 12 months. The company plans to submit a supplemental NDA for WAKIX for Idiopathic Hypersomnia (IH) in Q4 2024.
• Pipeline Milestones:
  • ZYN002 (Fragile X): Topline data from Phase 3 RECONNECT study expected mid-2025.
  • EPX100 (Epilepsy): Phase 3 trial for Lennox-Gastaut Syndrome planned for initiation in Q4 2024.
  • Pitolisant Formulations: Pivotal bioequivalence studies for Pitolisant GR and HD targeted for initiation in 2025.
• Legal Risks: The company is engaged in patent infringement litigation against multiple generic manufacturers (Lupin, Novugen, Novitium, Zenara, AET, Annora, MSN) seeking approval for generic WAKIX. A consolidated trial is scheduled for February 2026. An adverse outcome could materially impact future revenue.
• Share Repurchases: No shares were repurchased in the first nine months of 2024. $150M remains authorized under the October 2023 program.

Key Facts for Investor Verification

• Customer Concentration: Three customers (CVS Caremark, Accredo, Pantherx) accounted for 100% of gross accounts receivable and 100% of gross product revenue for the nine months ended Sept 30, 2024.
• Patent Expiration: Key patents for WAKIX expire in 2026, 2029, and 2030. The company is actively litigating against generic entrants.
• Acquisition Milestones: The Epygenix acquisition includes potential future payments of up to $130M for development/regulatory milestones and $515M for sales milestones.
• Debt Covenants: The company is in compliance with all covenants under its Term Loan A Credit Agreement as of Sept 30, 2024.
• Inventory: The company has adequate WAKIX supply to cover demand into Q1 2026, with API inventory supporting at least 24 months beyond that.